Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Down 57.3% in December

Pyxis Oncology, Inc. (NASDAQ:PYXS) saw a large drop in short interest in December. As of December 15th, there was short interest totaling 1,933,041 shares, a drop of 57.3% from the November 30th total of 4,523,744 shares. Currently, 3.5% of the shares of the stock are short sold. Based on an average daily volume of 645,262 shares, the short-interest ratio is currently 3.0 days. Based on an average daily volume of 645,262 shares, the short-interest ratio is currently 3.0 days. Currently, 3.5% of the shares of the stock are short sold.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in PYXS. Schulhoff & Co. Inc. grew its position in Pyxis Oncology by 125.4% in the 2nd quarter. Schulhoff & Co. Inc. now owns 275,000 shares of the company’s stock valued at $302,000 after acquiring an additional 153,000 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of Pyxis Oncology during the second quarter worth about $146,000. 683 Capital Management LLC boosted its stake in shares of Pyxis Oncology by 32.5% in the first quarter. 683 Capital Management LLC now owns 550,000 shares of the company’s stock valued at $539,000 after purchasing an additional 135,000 shares during the period. Catalyst Funds Management Pty Ltd acquired a new position in shares of Pyxis Oncology in the second quarter valued at approximately $26,000. Finally, Kingstone Capital Partners Texas LLC purchased a new stake in Pyxis Oncology during the 2nd quarter worth approximately $37,000. 39.09% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently weighed in on PYXS. Royal Bank Of Canada lowered their price target on shares of Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating on the stock in a research report on Thursday, December 18th. Guggenheim lifted their price objective on Pyxis Oncology from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Wall Street Zen cut Pyxis Oncology from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pyxis Oncology in a report on Wednesday, October 8th. Finally, HC Wainwright raised their price objective on shares of Pyxis Oncology from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $7.20.

Pyxis Oncology Price Performance

NASDAQ PYXS remained flat at $1.11 during trading hours on Friday. 1,611,444 shares of the company’s stock were exchanged, compared to its average volume of 1,614,458. The company has a market capitalization of $69.11 million, a PE ratio of -0.69 and a beta of 1.37. The firm has a fifty day moving average price of $3.79 and a 200-day moving average price of $2.38. Pyxis Oncology has a 52 week low of $0.83 and a 52 week high of $5.55.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.01. As a group, research analysts forecast that Pyxis Oncology will post -1.04 EPS for the current fiscal year.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical?stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody?drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off?target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early?stage ADC candidates directed against a variety of solid tumor antigens.